Adjuvant Trastuzumab Reduces Locoregional Recurrence in Women who Undergo Breast Conservation Therapy for Node-Negative HER2-Positive Breast Cancer

Abstract

Purpose/Objective(s): Patients with HER2-positive breast cancer have a higher risk of locoregional recurrence (LRR), even in the setting of lymph node-negative disease that is treated with breast conservation therapy (BCT). Whether adjuvant trastuzumab reduces the risk of LRR in these women is unknown, as these patients were often excluded or underrepresented in earlier randomized studies. In this retrospective, single institution study, we evaluated LRR in women with #5 cm, node-negative, HER2+ breast cancer who underwent BCT with or without adjuvant trastuzumab.